104 results about "Hapten" patented technology

The invention discloses a test strip for detecting etoxazole and application of the test strip. The test strip comprises a sample absorption pad (1), a conjugate release pad (2), a reaction film (3), a water absorption pad (4) and a bottom plate (7), the reaction film is provided with a detection line (5) coated with an etoxazole hapten-carrier protein conjugate and a quality control line (6) coated with a goat anti-mouse antibody, and the conjugate release pad (2) is sprayed with an etoxazole monoclonal antibody-colloidal gold marker. The invention also provides a method for detecting residual etoxazole in vegetables and fruits by using the etoxazole test strip. The test strip provided by the invention has the characteristics of simplicity in operation, high sensitivity, high detection speed, low cost and the like, and is suitable for screening and on-site monitoring of a large number of samples.

To provide a method for solving problems related to the delivery of R2 polyhapten reagents, such as short delivery times or bubble collapse. [Solution] A novel and improved method for separating absorbance caused solely by the addition of assay reagents, and a novel and improved method for detecting and flagging problems, particularly those caused by the delivery of R2 polyhapten reagents, as well as apparatus and compositions for use herein, are provided.

This application relates to a detection reagent, kit, and method that simultaneously improves sensitivity and broadens the detection range in competitive immunoassay. The reagent includes a detection antibody bound to luminescent microspheres that specifically binds to analyte molecules in the sample, and two sets of labeled antigens containing the same competing antigen and labeled molecules of different molecular weights bound to it. The competing antigen competes with the analyte molecule for binding to the detection antibody, and the affinity of the competing antigen for binding to the detection antibody is higher than that of the analyte molecule for binding to the detection antibody. The technical solution of this application, by using two sets of labeled antigens with different affinities, ensures that the labeled antigens that play a dominant role in samples with varying concentrations of analyte molecules differ. This is suitable for competitive immunoassay of small molecule antigens or haptens in both low-concentration and high-concentration samples, and can broaden the detection range while ensuring high functional sensitivity.

To provide RPA compositions and methods for detecting the presence or absence of a target nucleic acid using a dual-hapten probe.SOLUTION: This disclosure relates to methods and compositions for detecting a target nucleic acid sequence using a dual-hapten probe. More specifically, the present disclosure relates to detection of a target nucleic acid sequence using recombinase polymerase amplification (RPA) and a dual-hapten probe. In some cases, the detection is on lateral flow strips.SELECTED DRAWING: Figure 4

The application discloses a kind of rice mycotic acid hapten and antigen preparation application, it is related to antigen preparation technical field, introduce sulfydryl in the 2 of rice mycotic acid, and obtain rice mycotic acid antigen by coupling with protein through connecting arm, rice mycotic acid hapten and antigen preparation application include the following specific flow: S1, the synthesis of rice mycotic acid hapten;S2, the preparation of rice mycotic acid immunogen;S3, the preparation of rice mycotic acid coating original;S4, the preparation of rice mycotic acid monoclonal antibody;S5, the preparation of rice mycotic acid immunofluorescence detection card;S6, rice mycotic acid detection in food;S7, detection limit experiment;S8, false positive rate, false negative rate experiment.The rice mycotic acid hapten retains the structural characteristics of rice mycotic acid, better exposes rice mycotic acid structural characteristics, improves the immunity and immune recognition ability of antigen, lays foundation for preparing specific, high sensitivity antibody, and improves its rapid detection ability.

This invention belongs to the field of immunology and discloses a hybridoma cell line and the preparation and application of its secreted monoclonal antibody that uniformly recognizes tylosin / tilmicosin. The monoclonal antibody hybridoma cell line is named DES-AOAA-14D5, with accession number CGMCC NO: 45303. This invention utilizes decarboxymethyl tylosin and oxycarboxymethyl hydroxylamine to synthesize a hapten, conjugates a carrier protein to prepare a complete antigen, immunizes mice, and, through cell fusion and screening techniques, prepares a hybridoma cell line that can secrete a monoclonal antibody that uniformly recognizes tylosin / tilmicosin. IC50 50 The effective concentrations were 1.59 and 1.72 ng / mL, respectively, with a cross-reactivity rate as high as 92.44%. An immunoassay method for the simultaneous and accurate detection of tylosin / tilmicosin in milk was established using this antibody. The cut-off value for both tylosin and tilmicosin was 16 ng / mL, and no cross-reactivity was observed with other structural analogs. The detection method of this invention shows promising application prospects.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

A nanoparticle vaccine composition includes a shell including one or more amphiphilic molecules and one or more hapten molecules, where at least one amphiphilic molecule is conjugated to the hapten molecule, and a substantially hydrophobic core including an immunogenic protein, a vaccine adjuvant, one or more inert biocompatible materials, or a combination of two or more thereof, where the core is encapsulated in the shell to form a nanoparticle.

This invention relates to a medemididine hapten, a complete antigen, and their preparation methods and applications. The structure of the medemididine hapten is shown in Formula I. The preparation method of the medemididine hapten includes: (1) substituting medemididine with ethyl 3-bromopropionate to obtain intermediate 2; (2) adding sodium hydroxide to deprotect the ester group to obtain medemididine hapten 3. The structure of the complete antigen is shown in Formula II. The preparation method of the complete antigen includes: coupling the medemididine hapten with a carrier protein to obtain the complete antigen. This invention discloses a method for preparing medemididine hapten and complete antigen. The synthesis steps are simple and effective, and it can be used in immunoassay. Among them, colloidal gold immunochromatography is simple to operate, has a short detection time, high specificity, and good reproducibility, which can meet the domestic demand for immunoassay of medemididine.

The invention relates to preparation of a cyclic adenosine monophosphate (cAMP) detection kit by using a chemiluminescence immunoassay technology. Cyclic adenosine monophosphate is an important second messenger for cell signal transduction and has wide physiological functions. Cyclic adenosine monophosphate is small in molecular weight and poor in immunogenicity, so that when a corresponding antibody is prepared, a proper derivative site needs to be selected firstly, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic adenosine monophosphate hapten, preparation of a cyclic adenosine monophosphate complete antigen and an anti-cyclic adenosine monophosphate antibody, a method for measuring the concentration of cyclic adenosine monophosphate, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic adenylate derivative. The cyclic adenylic acid derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

Compositions, kits, and systems containing tolythiazine haptens, immunogens, and / or protein conjugates are disclosed. Methods of producing and using the tolythiazine haptens, immunogens, and conjugates are also disclosed.

The invention relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology. Cyclic guanylate is small in molecular weight and poor in immunogenicity. When a corresponding antibody is prepared, a proper isomer and a derivative site need to be selected firstly, and a derivative hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic guanylic acid hapten, a cyclic guanylic acid complete antigen, preparation of an anti-cyclic guanylic acid antibody, a method for measuring the concentration of cyclic guanylic acid, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic guanylate derivative. The cyclic guanylate derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

Conjugates comprising a viral targeting ligand (e.g., an influenza virus targeting ligand), a linker, and a plurality of haptens are described. Also described are pharmaceutical compositions comprising the conjugates and methods of using the conjugates to treat viral infections or prevent such infections.

The present disclosure describes a peptide scaffold for producing vaccines. The peptide scaffold includes a peptide that self-assembles into a hapten carrier (hC) includes amphipathic alpha-helices. The peptide includes heptad repeats following a specific pattern. The hC further includes hapten or an agent conjugated to it, and optionally the hC includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the hapten-hC or agent-hC conjugate.

The present application relates to the technical field of hapten, in particular to vitamin D3 carboxylic acid derivative, antigen and preparation method thereof. The structural formula of vitamin D3 carboxylic acid derivative is shown as follows: the vitamin D3 carboxylic acid derivative has excellent antibody binding activity, the vitamin D3 antigen coupled has high activity and inhibition rate. And the synthesis cost of the vitamin D3 carboxylic acid derivative is low, the cycle is short, and the yield is high.

The present application relates to a hybridoma cell strain secreting clozapine and its metabolite monoclonal antibody, and belongs to the technical field of immune detection. The present application prepares a hapten by chemically synthesizing clozapine and its metabolite, and then prepares a complete antigen, and then screens a hybridoma cell strain secreting clozapine and its metabolite monoclonal antibody through animal immunization and cell fusion. The hybridoma cell strain LDP-2B10 provided by the present application has been preserved in the China General Microbiological Culture Collection Center (CGMCC) with a preservation number of CGMCC No. 46233. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity, the IC 50 value of the monoclonal antibody for clozapine is 5.041 ng / mL, the IC 50 value of the monoclonal antibody for the metabolite N-desmethylclozapine is 5.524 ng / mL, and the IC 50 value of the monoclonal antibody for the metabolite clozapine-N-oxide is 5.551 ng / mL. The cross reactivity of the monoclonal antibody for various clozapine functional analogues is less than 1%, and the monoclonal antibody can be used for detecting clozapine in urine and blood drug concentration, and has practical application value.

The invention discloses a chloramphenicol hapten, antigen, antibody and colloidal gold detection device as well as a preparation method and application thereof. According to the chloramphenicol hapten prepared by using a total synthesis method, all potential recognition sites of chloramphenicol are reserved to the maximum extent, particularly, the most critical dichloro structure of chloramphenicol is reserved for the first time, after a spacer arm is introduced, the distribution of electron cloud of the hapten is almost consistent with that of overall electron cloud of chloramphenicol, and the immunogenicity of the chloramphenicol antigen is improved; the chloramphenicol antigen and the monoclonal antibody prepared by the invention are high in specificity when being used for ELISA detection, the IC50 value is 8.21 pg / mL, the linear detection range is 1.71-39.45 pg / mL, and the cross reaction rates of the chloramphenicol antigen and the monoclonal antibody to common structural analogues are lower than 0.01%; and the sensitivity to chloramphenicol in a sample is 0.1 g / kg.

This invention relates to a hybridoma cell line that secretes a monoclonal antibody against Basic Yellow O and its application, belonging to the field of immunoassay. The hybridoma cell line of this invention was deposited on November 12, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46740. This invention obtains the Basic Yellow O hapten through multiple screenings and experiments, then prepares the Basic Yellow O complete antigen from the hapten, and uses this complete antigen to immunize animals to obtain a hybridoma cell line. The Basic Yellow O monoclonal antibody secreted by this cell line exhibits excellent affinity and sensitivity to Basic Yellow O, with an IC50 value of [missing information - likely a value]. 50 With a concentration of 1 ng / mL, it can be used to prepare immunoassay products for Basic Yellow O, providing an efficient detection method and means for the detection of Basic Yellow O residues in food.

Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.

The application discloses a new type of hapten and fatty acid double modified long-acting hypoglycemic BimBH3 mimetic peptide compound targeting PTP1B as well as a preparation method and application thereof. The structural general formula of the Bim BH3 mimetic peptide is shown as formula I: wherein the compound is derived from a core region peptide segment of a Bim-BH3 domain, a non-natural amino acid is used to replace the second amino acid by site-specific substitution to increase the stability of the peptide segment against DPP-4 enzyme, and a long-chain fatty acid (hexadecanoic acid or octadecanedioic acid) is conjugated to the N terminal to modify to ensure better PTP1B inhibitory activity, so that the BimBH3 mimetic peptide has longer duration and higher activity and plays a role in hypoglycemia by inhibiting the target PTP1B. The compounds are prepared by using 2-CTC resin by polypeptide solid-phase synthesis method, and the crude product is cut, purified and freeze-dried to obtain a pure target compound.

This invention relates to a cicutine hapten, a hybridoma cell line, an antibody, and their applications, belonging to the field of immunochemistry. The hybridoma cell line, ISO 400, is deposited at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, on April 18, 2024, with accession number CGMCC No. 45918. The monoclonal antibody secreted by the cell line provided by this invention exhibits good detection sensitivity (IC50) for cicutine. 50 With a value of 9.69 μg / mL and high specificity, it enables rapid detection of coniine, providing raw materials for the immunoassay of coniine in hemlock and cosmetics, and has practical application value.

Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.

The application discloses a redox response carrier protein and application thereof in preparation of vaccines, wherein at least one hapten structure is chemically coupled and modified on the carrier protein through a connecting arm containing a disulfide bond structure, and the hapten structure is selected from one of dinitrobenzene, galactose-alpha-(1,3)-galactose, rhamnose and phosphorylcholine. The redox response disulfide bond connecting arm can modify the hapten to the carrier protein, and can be recognized and combined by the naturally existing antibody in the body to form a complex, promote phagocytosis, processing and presentation of antigen presenting cells, thereby effectively improving the immunogenicity of the vaccine molecule and improving the antigen related immune response. After the redox disulfide bond connecting arm enters the lysosome, the disulfide bond is broken through response to the reducing property in the cell, lysosome escape occurs, cross-layer delivery of the antigen is realized, and the immunogenicity of the antigen is greatly improved.

The invention provides a hybridoma cell strain secreting a toxoflavin monoclonal antibody. The hybridoma cell strain is obtained by immunogen immune animals prepared by coupling toxoflavin hapten and carrier protein. Wherein the carrier protein for preparing the immunogen comprises keyhole limpet hemocyanin KLH. The hybridoma cell strain is preserved in the Guangdong Microbial Culture Collection Center on March 10, 2026, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No.67912. The invention also provides an application of the hybridoma cell strain, specifically, the toxoflavin monoclonal antibody secreted by the hybridoma cell strain is applied to toxoflavin detection. The kit further comprises a coating antigen, the coating antigen is prepared by coupling the toxoflavin hapten and carrier protein, and the carrier protein for preparing the coating antigen comprises bovine serum albumin (BSA). The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to toxoflavin, and can be accurately and reliably used for quantitative detection of toxoflavin in an actual sample.

Compositions, kits and systems containing pregabalin haptens, immunogens and / or protein conjugates are disclosed. Methods of producing and using the pregabalin haptens, immunogens, and conjugates are also disclosed.

Pharmaceutical compositions comprising a dual hapten conjugate for treating viral infections such as influenza; and methods for treating such infections are disclosed herein.

The present application relates to the field of immunoassay technology, and provides a myclobutanil hapten, antigen, antibody and preparation method and application. The present application introduces an active group at the meta position of the chlorine atom on the benzene ring of myclobutanil. Compared with the existing hapten, the hapten provided by the present application completely simulates the structure of myclobutanil, and enhances the immunogenicity of the antigen. The antigen provided by the present application has strong immunogenicity after being coupled with a carrier protein. After injection immunization of mice, the titer of the produced antibody is 5.0x10 4 , the half-inhibitory concentration (IC 50 ) is about 50 ppb, and the minimum detection limit of colloidal gold for myclobutanil in dry tobacco leaf samples is about 2.5 μg / g.

The application provides a benzopyrene immunoaffinity column and a preparation method and application thereof, and a filler of the benzopyrene immunoaffinity column comprises a solid carrier coupled with a benzopyrene monoclonal antibody. The benzopyrene monoclonal antibody in the benzopyrene immunoaffinity column is prepared by using a benzopyrene hapten-carrier protein conjugate as an immunogen, so that the antibody can specifically adsorb benzopyrene substances in petroleum chemicals, effectively improves the recovery rate of benzopyrene, reduces the interference of other impurities such as lipids, proteins and pigments in the petroleum chemicals, and improves the accuracy of benzopyrene detection.

The invention relates to preparation of a Uric acid detection kit by using a chemiluminescence immunoassay technology. Uric acid is small in molecular weight, poor in immunogenicity and many in-vivo analogues, so that an antibody prepared from a uric acid derivative designed by the uric acid is poor in specificity and is difficult to meet reagent detection requirements. According to the present invention, allantoin is innovatively used to prepare the hapten and the antibody, in the detection process, the uric acid in the sample only needs to be converted into the allantoin through the specific sample treatment liquid, and the content of the uric acid in the body is indirectly reflected by determining the concentration of the allantoin in the sample; the invention mainly relates to design and synthesis of an allantoin hapten, preparation of an allantoin complete antigen and an anti-allantoin antibody, a method for measuring the concentration of uric acid, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of an allantoin derivative. The allantoin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.